SAN FRANCISCO--(

旧金山--(

BUSINESS WIRE

商业热线

)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced significant milestones in its mission to transform healthcare delivery. In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world,

)--人工智能支持的疾病检测和智能护理协调领域的领导者Viz.ai今天宣布了其转变医疗保健服务使命的重要里程碑。2024年，该公司与世界上三家最大的全球制药公司建立了新的合作伙伴关系，

realizing a total of 10 partnerships with leading life science companies. Viz.ai expanded its reach to serve 1,700 hospitals with a broad user base that grew by more than 30% to reach 60,000 healthcare providers in the United States. This rapidly growing footprint, driven by new product innovation and real-world evidence, demonstrates the company’s commitment to increase access to life-saving treatments..

与领先的生命科学公司建立了总共10个合作伙伴关系。Viz.ai扩大了其服务范围，为1700家医院提供了广泛的用户基础，增长了30%以上，达到了美国60000家医疗保健提供者。在新产品创新和现实证据的推动下，这一快速增长的足迹表明，该公司致力于增加获得救生治疗的机会。。

“This year has surpassed our expectations as Viz.ai’s footprint in healthcare continued to grow with the majority of the 50 largest healthcare systems in the U.S. adopting our platform,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “This reaffirms Viz.ai’s position as the leading, trusted AI-powered platform and our dedication to delivering tools that empower providers, streamline workflows and improve patient outcomes.

Viz.ai首席执行官兼联合创始人克里斯·曼西博士表示：“今年，随着美国50个最大的医疗保健系统中的大多数采用我们的平台，Viz.ai在医疗保健领域的足迹持续增长，超过了我们的预期。”这重申了Viz.ai作为领先、值得信赖的人工智能平台的地位，以及我们致力于提供赋予提供者权力、简化工作流程和改善患者预后的工具。

As we continue to broaden our patient impact with leading life science collaborators and healthcare systems, we look to accelerate better patient care by leveraging AI-driven insights and care coordination in 2025.”.

随着我们与领先的生命科学合作者和医疗保健系统不断扩大对患者的影响，我们希望在2025年利用人工智能驱动的见解和护理协调来加速更好的患者护理。”。

In 2024, Viz.ai introduced new products and capabilities to its Viz.ai One™ enterprise platform, which now includes more than 48 clinical AI modules. Key innovations include the introduction of the Viz ICH Plus™ algorithm for automated volumetric assessment and cutting-edge 3D CT angiography functionality, as well as the launch of Viz Connect® for cryptogenic stroke and Viz ACS for acute coronary syndrome.

2024年，Viz.ai向其Viz.ai One™企业平台推出了新产品和功能，该平台现在包括48个以上的临床ai模块。主要创新包括引入用于自动体积评估的Viz ICH Plus™算法和尖端的3D CT血管造影功能，以及推出用于隐源性中风的Viz Connect®和用于急性冠状动脉综合征的Viz ACS。

These enhancements further strengthen Viz.ai’s offering in cardiovascular and neurovascular care pathways, enhancing functionality in both acute and non-acute treatment scenarios and underscoring the company’s commitment to transform healthcare through AI-driven solutions..

这些改进进一步加强了人工智能在心血管和神经血管护理途径中的提供，增强了急性和非急性治疗方案的功能，并强调了该公司通过人工智能驱动的解决方案转变医疗保健的承诺。。

With 24 new clinical studies this year and more than

今年有24项新的临床研究

100 clinical publications and abstracts

100篇临床出版物和摘要

to date, Viz.ai has continued to demonstrate substantial real-world evidence of the positive impact of its AI-powered care coordination on patient outcomes and economic efficiency. Three studies at the American College of Cardiology Scientific Session 2024 demonstrated the positive impact of Viz.ai’s hypertrophic cardiomyopathy module on suspected disease detection and patient triage for improved care.

迄今为止，Viz.ai继续证明其人工智能支持的护理协调对患者结局和经济效率产生积极影响的大量现实证据。2024年美国心脏病学会科学会议的三项研究表明，Viz.ai的肥厚型心肌病模块对疑似疾病检测和患者分诊有积极影响，以改善护理。

Another recent .

另一个最近的。

study

学习

on pulmonary embolism (PE)

关于肺栓塞（PE）

showed that the Viz PE solution significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk. Additionally,

结果表明，Viz-PE解决方案显着改善了评估时间和抗凝时间，住院死亡风险降低了74%。另外，

six studies

六项研究

presented at the International Stroke Conference (ISC) 2024

在2024年国际中风会议（ISC）上发表

showed the real-world impact of Viz.ai on positive outcomes in clinical practice for acute ischemic stroke, cryptogenic stroke, unruptured incidental cerebral aneurysms and brain hemorrhage.

显示了Viz.ai对急性缺血性卒中，隐源性卒中，未破裂的偶发性脑动脉瘤和脑出血的临床实践中的积极结果的现实影响。

Viz.ai formed new partnerships with leading healthcare technology organizations to further scale its impact. At the Radiological Society of North America (RSNA) meeting, Viz.ai announced a

Viz.ai与领先的医疗保健技术组织建立了新的合作伙伴关系，以进一步扩大其影响力。在北美放射学会（RSNA）会议上，Viz.ai宣布

collaboration with Microsoft

与Microsoft的协作

to deliver a comprehensive platform of more than 48 diagnostic imaging AI models seamlessly embedded into clinical workflows. Together, Viz.ai and Microsoft aim to help radiologists create more accurate reports more efficiently, streamline communication to treating physicians, and support care team collaboration for appropriate follow-up and treatment for patients.

提供一个由48多种诊断成像AI模型无缝嵌入临床工作流程的综合平台。Viz.ai和微软共同致力于帮助放射科医生更有效地创建更准确的报告，简化与治疗医生的沟通，并支持护理团队合作，为患者提供适当的随访和治疗。

Viz.ai announced a partnership with .

Viz.ai宣布与。

Cleerly

克莱利

at the American College of Cardiology meeting (ACC) and a partnership with

在美国心脏病学会会议（ACC）上与

Addario Lung Cancer Medical Institute

阿达里奥肺癌医学研究所

at the American Society of Clinical Oncology meeting to advance care across cardiology, oncology and neurology.

在美国临床肿瘤学会会议上，推进心脏病学，肿瘤学和神经病学的护理。

This past year, Viz.ai was recognized by

去年，Viz.ai被

Fast Company’s 50 Most Innovative Companies list

Fast公司50家最具创新性公司名单

, received the

，收到

Prix Galien Award

加利恩大奖赛

for Best Digital Health Solution in Pharma, and earned its second

获得制药行业最佳数字健康解决方案，并获得第二名

Edison Award

爱迪生奖

for Viz Pulmonary Embolism. Viz.ai CEO Dr Chris Mansi was also featured as one of the 100 most influential people in AI by

用于Viz肺栓塞。Viz.ai首席执行官克里斯·曼西博士还被《人工智能》杂志评为100位最具影响力的人物之一

TIME Magazine

《时代》杂志

. Collectively, these honors reflect the company’s innovation and impact on expanding patient access to life-saving treatments.

总的来说，这些荣誉反映了公司在扩大患者获得救生治疗方面的创新和影响。

About Viz.ai

关于Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes.

Viz.ai是使用ai算法和机器学习提高美国和欧洲1700家医院和卫生系统诊断和护理速度的先驱。AI-powered Viz.AI One™是一种智能护理协调解决方案，可识别更多疑似疾病患者，在护理点告知关键决策，优化护理途径并帮助改善结果。

Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai..

在现实世界的临床证据的支持下，Viz.ai One为患者，提供者以及制药和医疗器械公司提供了巨大的价值。有关更多信息，请访问viz。ai。。